

Evry, France, December 11th, 2003

ObeTherapy filled a PCT patent describing hit compounds for obesity, lipidemia and diabetes type II treatment.

ObeTherapy, a biotechnology company based at the Genopole® Biopark in Evry (France), announced today that a third patent was completed and deposited as PCT application; this patent was last year in a provisional application in USPTO.

The third patent, recently filled for a PCT protection, is the most important ObeTherapy's patent describing several chemical entities as potential lead compounds for obesity treatment said Itzik Harosh CSO of ObeTherapy.

This PCT patent will strengthen ObeTherapy patents portfolio which were granted during the years 2000 and 2002.

The first granted patent describes a rapid and sensitive biochemical assay adaptable for HTS. This tool will permit a rapid identification of hit compounds against our validated target for obesity treatment. This target has been selected by the ObeTherapy's approach consisting of looking for genes in people with a lean phenotype.

The second granted patent protects the use of our targets for obesity treatment.

ObeTherapy Biotechnology dedicates its research to new molecules for the treatment of obesity, hypercholesterolaemia and diabetes of type II. Dr Itzik Harosh, PhD, founder and CSO, is a specialist in molecular biology, HTS and drug discovery and has an international experience in the field of obesity. While most of Itzik's colleagues conduct their research on the genetic characterisation of obesity, the novel approach of ObeTherapy consists of the analysis of the mechanisms at work in slim phenotype. This approach permitted the identification of many potential therapeutic targets actually being validated.

Contact: Dr. Itzik Harosh, Founder and CSO

Tel. 33-160878904

Fax. 33-160878999

E. mail!: iharosh@obetherapy.com

<http://www.obetherapy.com>